Search research articles
Contact Us
Filters
Showing results (231-240 of 240) with videos related to
Page
of 24
Sort By:
You have reached the last page of results.
This site can display upto 240 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Biorxiv : the Preprint Server for Biology
|
May 13, 2026
mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion
Claudia Gentile, William W Feng, Sean M Lenahan, et al.
Cancer Discovery
|
August 5, 2025
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy
Simon Baldacci, Elliott J Brea, Francesco Facchinetti, et al.
Cancer Immunology Research
|
September 8, 2025
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Elliott J Brea, Simon Baldacci, Neil Savage, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 16, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
M Aldea, S Lenahan, M-A Locquet, et al.
Cancer Discovery
|
April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Seshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.
Nature
|
August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
Shilpa Singh, Catherine E Gleason, Min Fang, et al.
Physical Review Letters
|
September 26, 2025
GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes
A G Abac, I Abouelfettouh, F Acernese, et al.
Physical Review Letters
|
February 16, 2026
Black Hole Spectroscopy and Tests of General Relativity with GW250114
A G Abac, I Abouelfettouh, F Acernese, et al.
Page
of 24
Search research articles
Search
Showing results (231-240 of 240) with videos related to
Sort By:
Page
of 24
You have reached the last page of results.
This site can display upto 240 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Biorxiv : the Preprint Server for Biology
|
May 13, 2026
mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion
Claudia Gentile, William W Feng, Sean M Lenahan, et al.
Cancer Discovery
|
August 5, 2025
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy
Simon Baldacci, Elliott J Brea, Francesco Facchinetti, et al.
Cancer Immunology Research
|
September 8, 2025
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Elliott J Brea, Simon Baldacci, Neil Savage, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 16, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
M Aldea, S Lenahan, M-A Locquet, et al.
Cancer Discovery
|
April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Seshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.
Nature
|
August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
Shilpa Singh, Catherine E Gleason, Min Fang, et al.
Physical Review Letters
|
September 26, 2025
GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes
A G Abac, I Abouelfettouh, F Acernese, et al.
Physical Review Letters
|
February 16, 2026
Black Hole Spectroscopy and Tests of General Relativity with GW250114
A G Abac, I Abouelfettouh, F Acernese, et al.
Page
of 24